



ERIC HOLCOMB, GOVERNOR
STATE OF INDIANA

Office of Medicaid Policy and Planning
MS 07, 402 W. WASHINGTON STREET, ROOM W382
INDIANAPOLIS, IN 46204-2739

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee
November 4, 2022

Virtual Meeting - Microsoft Teams Link Provided Below

1. Call to Order-Chair
2. Preferred Drug List: Therapeutic Class Re-Review - Discussion and Recommendations
3. Preferred Drug List: Therapeutic Class Re-Review
 - a. CNS and Others
 - i. Agents for the Treatment of Opiate Addiction
 - ii. Antiemetic/Antivertigo Agents
 - iii. Antiseizure Agents
 - iv. Gastroprotective NSAIDs
 - v. Movement Disorder Agents
 - vi. Narcotic Antitussive/1st Generation Antihistamine Combinations
 - vii. Narcotics
 - viii. Skeletal Muscle Relaxants
 - ix. Smoking Deterrent Agents
 - b. Dermatologic Agents
 - i. Acne Agents
 - ii. Antipsoriatic Agents
 - c. Endocrine
 - i. Anaphylaxis Agents



- ii. Bone Formation Stimulating Agents
- iii. Bone Resorption Inhibitors
- iv. DPP-4 Inhibitors and Combination Agents
- v. GLP-1 Receptor Agonists and Combinations
- vi. Glucagon Agents
- vii. Growth Hormones
- viii. Injectable Hypoglycemics, Insulin
- ix. Miscellaneous Oral Antidiabetic Agents
- x. SGLT2 Inhibitors and Combinations
- xi. Testosterones
- d. Estrogen and Related Agents
 - i. Estrogen and Related Agents
 - ii. Contraceptives
- e. Gastrointestinal Agents
 - i. Anti-ulcer Agents
 - ii. *H. Pylori* Agents
 - iii. H2 Receptor Antagonists
 - iv. Laxatives and Cathartics
 - v. Pancreatic Enzymes
 - vi. Proton Pump Inhibitors
 - vii. Ulcerative Colitis Agents
- f. Genitourinary Agents
 - i. Benign Prostatic Hypertrophy Agents
 - ii. Urinary Tract Antispasmodic/Anti-Incontinence Agents
- g. Hematologic Agents
 - i. Direct Factor Xa Inhibitors
 - ii. Direct Thrombin Inhibitors
 - iii. Hematinics
 - iv. Leukocyte (WBC) Stimulants
 - v. Platelet Aggregation Inhibitors
- h. Targeted Immunomodulators
- i. Topical Agents

- i. Dry Eye Disease or Keratoconjunctivitis
 - ii. Miotics-Intraocular Pressure Reducers
 - iii. Ophthalmic Antihistamines
 - iv. Ophthalmic Anti-Inflammatory Agents
 - v. Ophthalmic Mast Cell Stabilizers
 - vi. Otic Preparations
 - vii. Topical Anti-Inflammatory Agents-NSAIDs
 - viii. Topical Antiparasitics
 - ix. Topical Immunomodulators
 - x. Topical Post-herpetic Neuralgia Agents
4. Public Comment
5. Other Business
6. Adjourn

Microsoft Teams meeting

Join on your computer, mobile app or room device

[Click here to join the meeting](#)

Meeting ID: 220 774 592 539

Passcode: rRiAbL

[Download Teams](#) | [Join on the web](#)

Join with a video conferencing device

425899727@t.plcm.vc

Video Conference ID: 118 855 352 96

[Alternate VTC instructions](#)

Or call in (audio only)

[+1 952-222-7450,,410522243#](#) United States, Bloomington

Phone Conference ID: 410 522 243#

[Find a local number](#) | [Reset PIN](#)